Compare · LUNG vs MDLN
LUNG vs MDLN
Side-by-side comparison of Pulmonx Corporation (LUNG) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNG and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 436.4x LUNG ($107.4M).
- Over the past year, LUNG is up 38.2% and MDLN is down 14.3% - LUNG leads by 52.5 points.
- MDLN has been more active in the news (12 items in the past 4 weeks vs 2 for LUNG).
- MDLN has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Pulmonx Corporation
- Medline Inc.
- Price
- $2.46-2.38%
- $34.93-1.99%
- Market cap
- $107.4M
- $46.86B
- 1M return
- +95.24%
- -13.81%
- 1Y return
- +38.20%
- -14.32%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 2
- 12
- Recent ratings
- 17
- 25
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Latest LUNG
- Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation
- SEC Form 10-Q filed by Pulmonx Corporation
- Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pulmonx Reports Second Quarter 2026 Financial Results
- Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
- Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
- Director Burns Thomas William was granted 40,000 shares, increasing direct ownership by 54% to 113,399 units (SEC Form 4)
- Director Ferrari Richard was granted 40,000 shares, increasing direct ownership by 46% to 127,024 units (SEC Form 4)
- Director Florin Daniel P was granted 40,000 shares, increasing direct ownership by 43% to 133,910 units (SEC Form 4)
- Director Melenikiotou Georgia was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.